CUDC‐907, a novel dual PI3K and HDAC inhibitor, in prostate cancer: Antitumour activity and molecular mechanism of action

Targeting the androgen receptor (AR) signalling pathway remains the main therapeutic option for advanced prostate cancer. However, resistance to AR‐targeting inhibitors represents a great challenge, highlighting the need for new therapies. Activation of the PI3K/AKT pathway and increased expression...

Descripción completa

Detalles Bibliográficos
Autores principales: Hu, Cheng, Xia, Hongyan, Bai, Shanshan, Zhao, Jianlei, Edwards, Holly, Li, Xinyu, Yang, Yanrong, Lyu, Jing, Wang, Guan, Zhan, Yang, Dong, Yan, Ge, Yubin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7339177/
https://www.ncbi.nlm.nih.gov/pubmed/32459381
http://dx.doi.org/10.1111/jcmm.15281

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7339177/
https://www.ncbi.nlm.nih.gov/pubmed/32459381
http://dx.doi.org/10.1111/jcmm.15281

Ejemplares similares